 After the FDA provided an update on the agencys response to the monkeypox outbreak on July 29th, investors misunderstood the FDAs statements, and the stock sold off 33 and shortly reverted. SIGAs monkeypox treatment TPOXX is already approved in the U.S., EU, and Canada for smallpox andor monkeypox, further de-risking the equity story. 